The objectives of the this study were to assess the influence of CYP3A5 genotype and sex on the variability in total CYP3A activity and to compare 4b-hydroxycholesterol and omeprazole sulfoxidation as phenotypic markers for CYP3A activity in Ethiopians. Healthy subjects (n ¼ 150) were genotyped for CYP3A5*3, *6 and *7 using allele-specific PCR and Taqman genotyping assays. Plasma levels of 4b-hydroxycholesterol, 3 h post-dose omeprazole and omeprazole sulfone, were determined by gas chromatography-mass spectrometry and high performance liquid chromatography, respectively. The frequency of CYP3A5*1, *3, *6 and *7 was 20.5, 67.3, 12.2 and 0%, respectively. The mean plasma 4b-hydroxycholesterol level was 35.4 ng ml
Introduction
The cytochrome P450 (CYPs) 3A family metabolizes a large number of endogenous as well as exogenous substances. CYP3A4 is the most important drug-metabolizing enzyme and the most abundant CYP in human liver and small intestine. The human CYP3A subfamily includes CYP3A4, CYP3A5, CYP3A7 and CYP3A43. CYP3A43 is expressed at very low levels in adult livers, accounting for only 0.1-0.2% of CYP3A4 transcripts.
1 CYP3A7 is primarily expressed in the fetal liver 2 but can also be present in small amounts in some adult livers. 3 The contribution of CYP3A43 and CYP3A7 to the metabolism of CYP3A substrates in adults is therefore thought to be negligible. 1, 3 The total CYP3A catalytic activity is thus mainly because of CYP3A4 and CYP3A5. 4 Most substrates for CYP3A4 are also metabolized by CYP3A5, although the relative contribution of CYP3A5 to CYP3A-mediated metabolism may differ for different substrates. 5, 6 Owing to overlapping substrate specificities between CYP3A5 and CYP3A4, it is difficult to segregate the relative contributions of the two enzymes to CYP3A-mediated metabolism. Omeprazole is metabolized into 5-hydroxyomeprazole and omeprazole sulfone by CYP2C19 and CYP3A4, respectively. The metabolic ratio of omeprazole to omeprazole sulfone has been proposed as a measure of CYP3A4 activity in vivo. 7 We recently reported the use of plasma 4b-hydroxycholesterol as a new endogenous CYP3A marker. 8 The relative contribution of CYP3A4 and CYP3A5 to the formation of 4b-hydroxycholesterol or omeprazole sulfone is also not clear but could be estimated by genotypephenotype correlations. In addition, sex differences in the metabolism of some of the CYP3A substrates have been reported but the issue remains controversial. [9] [10] [11] Extensive inter-individual and inter-ethnic variability in constitutive CYP3A expression and enzyme activity and hence variations in disposition of CYP3A substrates have been described. 8, [12] [13] [14] Environmental and genetic factors have significant roles to determine individual variability in CYP expression and enzyme activity. Indeed, CYP3A4 is genetically polymorphic with more than 20 variant alleles described so far. However, the current understanding implies no significant contribution of genetic variation in CYP3A4 to fully explain the observed variability in constitutive CYP3A activity because either the variants are relatively uncommon or have limited functional significance. 4 Previously, CYP3A5 was considered less important than CYP3A4 because it appeared to be expressed in few individuals and have a limited metabolic capability. 15 It gained much attention after Kuehl et al. 12 reported that when expressed, CYP3A5 represents at least 50% of the total hepatic CYP3A content. Interestingly, CYP3A5 is expressed mainly in black populations (60%) and much less in Whites (33%) and Asians. 12 Owing to the polymorphic expression and the presence of common defective variants alleles with wide inter-ethnic variations in their distribution, CYP3A5 may be the most important genetic contributor to interindividual differences in CYP3A-dependent drug clearance and treatment response.
Being highly polymorphic, CYP3A5 may have a significant role in determining inter-individual variations in drug response mainly in subjects of African origin. Few studies have investigated the genetic polymorphisms in CYP3A5 in African populations. 8, 13, 16 However, data from these studies cannot be extrapolated to other populations in the continent because Africans are heterogeneous with respect to pharmacogenetics of drug-metabolizing enzymes. 17, 18 This study aimed at investigating the influence of CYP3A5 genotype and sex on the CYP3A phenotype and compared the use of plasma 4b-hydroxycholesterol and omeprazole to omeprazole sulfone ratio as CYP3A markers. The results indicate the importance of sex and CYP3A5 genotype in determining total CYP3A activity. We found a unique distribution of CYP3A5 variants alleles and unprecedented high total CYP3A activity in Ethiopians compared with other populations described earlier.
Materials and methods

Subjects
One hundred fifty (79 female and 71 male) unrelated and healthy students from various parts of the country attending college of the Health Sciences, Bahirdar University, Ethiopia participated in the study. The age range was from 19 to 28 years (21.81 ± 1.69, mean ± s.d.) and body weight ranged from 44 to 63 kg (52.75±3.94, mean±s.d.). The subjects abstained from taking any medication during the study and physical examination showed no antecedent history of illness. Each subject was given a 20 mg capsule of omeprazole before breakfast (B8:00 am). In all, 10 ml blood sample was collected 3 h after drug intake for genomic DNA isolation and determination of omeprazole and its metabolites as well as for 4b-hydroxycholesterol and cholesterol concentrations. All participants gave their written informed consent. The study was approved by IRB of the School of Pharmacy, Addis Ababa University and by the National Health Research Ethics Review Committee, Addis Ababa, Ethiopia.
Phenotyping Plasma levels of 3 h post-dose omeprazole and its metabolites, 5-hydroxyomeprazole and omeprazole sulfone were quantified using reversed-phase high performance liquid chromatography (Shimadzu, Tokyo, Japan) as described elsewhere. 19 The day-to-day coefficient of variation for 5-hydroxyomeprazole, omeprazole, internal standard and omeprazole sulfone was 2.19, 4.35, 4.41 and 3.11% respectively. The omeprazole/omeprazole sulfone metabolic ratio was used as an index for CYP3A activity. 7 Plasma samples for determination of cholesterol and 4b-hydroxycholesterol were packed in dry ice and sent to Karolinska Institutet, Stockholm, Sweden. Cholesterol levels were measured by a commercial enzymatic method (Cholesterol CHOD-PAP, Roche Diagnostics GmbH, Mannheim, Germany). Determination of 4b-hydroxycholesterol was performed by gas chromatography-mass spectrometry using deuterium labeled 4b-hydroxycholesterol as internal standard. The plasma samples were subjected to alkaline hydrolysis and analyzed as described earlier. 20 The relative between-day variation was 5.4% (at 20 ng ml À1 ). Although 4b-hydroxycholesterol was determined in 149 subjects, cholesterol levels were measured only in 124 subjects.
Genotyping
Genomic DNA was isolated from blood leukocytes with E.Z.N.A Blood DNA kit (Omega Bio-tek, Doraville, GA, USA). All 150 subjects were genotyped for the common CYP3A5
Influence of sex and CYP3A5 genotype on total CYP3A activity SNPs namely CYP3A5*3, CYP3A5*6 and CYP3A5*7. Genotyping for CYP3A5*3 and CYP3A5*6 was performed using a Taqman genotyping assay on the ABI 7500 FAST (Applied Biosystems, Foster City, CA, USA). Genotyping for CYP3A5*7 was done using allele-specific PCR as described earlier. 13 
Data analysis
Haplotype analysis was performed using Arlequin version 3.1 to assess possible linkage between the different CYP3A5 SNPs. The Shapiro-Wilk W-test was used to investigate normality of distribution. Normality was assured by conversion of the data to log 10 values before statistical analysis. Log omeprazole/5-hydroxyomeprazole ratio was used as a covariate to control for the effect of CYP2C19 in all statistical analyses involving omeprazole/omeprazole sulfone ratio. Linear regression was performed to examine correlations between omeprazole/omeprazole sulfone, 4b-hydroxycholesterol and 4b-hydroxycholesterol/cholesterol ratio. Genotype-phenotype correlations were investigated using ANOVA/ANCOVA. Po0.05 was considered as statistically significant and all statistical analyses were performed using the software Statistica version 7.
Results
CYP3A phenotype
Omeprazole/5-hydroxyomeprazole, omeprazole/omeprazole sulfone, plasma 4b-hydroxycholesterol and cholesterol levels were not normally distributed and hence data were log transformed before statistical analysis. The omeprazole/ 5-hydroxyomeprazole ratio was used to determine CYP2C19 phenotype. CYP3A activity was determined using omeprazole/omeprazole-sulfone, 4b-hydroxycholesterol and 4b-hydroxycholesterol/cholesterol ratio as indexes. The median, mean ± s.d. values for omeprazole/5-hydroxyomeprazole and omeprazole/omeprazole-sulfone ratio, 4b-hydroxycholesterol and cholesterol are shown in Table 1 .
Correlations between 4b-hydroxycholesterol and omeprazole/ omeprazole sulfone Relationships between plasma omeprazole/omeprazole sulfone ratio and 4b-hydroxycholesterol or 4b-hydroxycholesterol/cholesterol ratio were examined in all subjects and also based on CYP2C19 phenotype or CYP3A5 genotype groups separately. The omeprazole/omeprazole sulfone ratio was significantly correlated to the 4b-hydroxycholesterol level and also to the 4b-hydroxycholesterol/cholesterol ratio in all subjects, in CYP2C19 extensive metabolizers (log omeprazole/5-hydroxyomeprazole ratio o0.8) and in CYP3A5 non-expressors (subjects homozygous for the defective CYP3A5*3 or CYP3A5*6 alleles, CYP3A5*0/'0) (Figure 1 ). However, no correlation of the omeprazole/omeprazole sulfone ratio with the 4b-hydroxycholesterol level or with the 4b-hydroxycholesterol/cholesterol ratio was observed among CYP2C19 poor meatbolizers (omeprazole/5-hydroxyomeprazole ratio X0.8, n ¼ 9) or subjects with CYP3A5*1/*0 (n ¼ 45) or the CYP3A5 *1/*1 genotype (n ¼ 8).
Sex-related differences in total CYP3A activity Both 4b-hydroxycholesterol and omeprazole/omeprazole sulfone ratios were examined for correlation with sex. ANCOVA using log omeprazole/5-hydroxyomeprazole ratio as a covariate indicated no significant difference in omeprazole/omeprazole sulfone between women and men. In contrast ANOVA analysis showed significant influence of sex with 4b-hydroxycholesterol (P ¼ 0.0001, F ¼ 12.15). We further investigated whether there was a significant difference in plasma cholesterol level between women and men. The result indicated a significantly higher mean plasma cholesterol level in women than in men. However, the mean 4b-hydroxycholesterol/cholesterol ratio remained significantly higher in women than in men (P ¼ 0.004, F ¼ 8.73) Table 2 .
CYP3A5 genotype and allele frequency
The frequencies of CYP3A5*3 and CYP3A5*6 were 67.3 and 12.2%, respectively. Interestingly, CYP3A5*7 was not detected. The allele frequency of CYP3A5*1 was 20.5%. Haplotype analysis indicated no linkage between CYP3A5*3 and CYP3A5*6. A list of the different CYP3A5 haplotypes and their frequencies among Ethiopians as compared to frequencies in Swedes, Koreans, African American and other African populations from the literature is shown in Table 3 .
CYP3A5 genotype and phenotype correlation No significant correlations between the number of functional alleles of CYP3A5 (CYP3A5*1) and omeprazole/omeprazole sulfone ratio were observed (ANCOVA, P ¼ 0.78, F ¼ 0.22) regardless of CYP2C19 activity using omeprazole/5-hydroxyomeprazole ratio as a covariate. However, there was significant correlation of CYP3A5 genotype with 4b-hydroxycholesterol (P ¼ 0. Influence of sex and CYP3A5 genotype on total CYP3A activity E Gebeyehu et al 4b-hydroxycholesterol level and the mean 4b-hydroxycholesterol/cholesterol ratio were significantly higher in subjects with two functional alleles (CYP3A5*1) as compared with subjects homozygous for the defective CYP3A5*3 or CYP3A5*6 alleles (CYP3A5*0/*0). The mean±s.d. value of omeprazole/omeprazole sulfone ratio, 4b-hydroxycholesterol and 4b-hydroxycholesterol/cholesterol ratio among subjects with different numbers of the functional CYP3A5*1 allele are listed in Table 4 . There was no correlation of CYP3A5 genotype with cholesterol level (P ¼ 0.43, F ¼ 0.65). Main effect ANOVA indicated that both sex (P ¼ 0.00001, F ¼ 29.32) and CYP3A5 genotype determined plasma 4b-hydroxycholesterol concentration (P ¼ 0.001, F ¼ 6.57) as well as the 4b-hydroxycholesterol/cholesterol ratio (P ¼ 0.0008, F ¼ 7.55). Comparing subjects with CYP3A5*0/*0 genotype only, there were significant differences in 4b-hydroxycholesterol (P ¼ 0.00001) and 4b-hydroxycholesterol/cholesterol ratio (P ¼ 0.007) between men (mean ± s.d.; 4b-hydroxycholesterol ¼ 29.6 ± 7.96 ng ml
À1
, 4b-hydroxycholesterol/cholesterol ratio ¼ 9.6±2.62) and women (mean±s.d.; 4b-hydroxycholesterol ¼ 38.1 ± 8.9 ng ml À1 , 4b-hydroxycholesterol/cholesterol ratio ¼ 11.21 ± 2.54).
Discussion
This study investigated the influence of CYP3A5 genetic polymorphisms as well as sex on CYP3A enzyme activity and also compared omeprazole sulfoxidation and cholesterol 4b-hydroxylation as total CYP3A markers in Ethiopians. The major findings were (1) CYP3A5 genotype influence total CYP3A activity in Ethiopians. (2) Women display higher CYP3A activity than men. (3) CYP3A5 genotype correlated with plasma 4b-hydroxycholesterol concentration but not with omeprazole/omeprazole sulfone ratio demonstrating that 4b-hydroxycholesterol is a better maker than omeprazole/ omeprazole sulfone ratio for total CYP3A activity. (4) Ethiopians display a unique distribution of CYP3A5 genetic variants and higher 4b-hydroxycholesterol concentrations than any other population reported so far.
As indicated in Table 3 , Ethiopians display a unique distribution of CYP3A5 genetic variant alleles as compared with other Africans, African Americans, Swedes and Koreans. The functional CYP3A5 variant allele, CYP3A5*1 is the most frequent variant allele in the black population (B50%) 8, 13, 16 , whereas in Ethiopians, the defective variant allele (CYP3A5*3) is the most frequent allele (67%). The lower frequency of CYP3A5*1 and absence of the black population-specific allele, CYP3A5*7, differentiate Ethiopians from other black Africans and African Americans with respect to CYP3A5 allele frequency distribution. On the other hand, the presence of CYP3A5*6 at a comparable Table 4 Comparison of mean plasma omeprazole/omeprazole sulfone ratio, plasma 4b-hydroxycholesterol concentration and 4b-hydroxycholesterol/cholesterol ratio among subjects with different numbers of functional CYP3A5 alleles (CYP3A5*1)
CYP3A marker
Number of CYP3A5*1alleles Influence of sex and CYP3A5 genotype on total CYP3A activity E Gebeyehu et al frequency as in black Africans and African Americans differentiate Ethiopians from Swedes and Koreans. The genetic diversity of sub-Saharan African populations has been greatly affected by the Bantu expansion. 21 Despite population genetic admixture, there are still concentrations of particular alleles in different African population groups, for instance, a high prevalence of CYP2D6 gene duplication among Ethiopians (29%) who are classified as Cushitics under the Afro-Asiatic language family compared to a low prevalence (1-2%) among Bantu Africans of the NigerCongo language family (for example, Ghanaians, Zimbabweans, Tanzanians). 17, 22 Similarly, Ethiopians display a higher frequency of CYP2D6*10 and CYP2C19*3, 23 which are by far the most frequent alleles in Asians. An Asianspecific mtDNA haplotype that is absent in other African or Caucasoid lineages is found in Ethiopians. 24, 25 Both linguistic and genetic studies show that most sub-Saharan populations are closely related to each other whereas Pygmys, Khoisans and Ethiopians are the most differentiated. 21 Genetic markers and Y chromosomal haplogroup distributions indicated that the gene pool of Ethiopians displays both western Eurasian and sub-Saharan genetic influences. [25] [26] [27] We assume that the population genetic structure that differentiates Ethiopians from other Africans accounts for their unique distribution of CYP3A5 variant alleles.
Ethiopians display not only a different distribution of CYP3A5 variant alleles but also a significantly (P ¼ 0.0001) higher mean 4b-hydroxycholesterol level (35.4 ng ml À1 ) as well as a higher 4b-hydroxycholesterol/cholesterol ratio compared to Swedes, Koreans and Tanzanians. The mean plasma concentrations of 4b-hydroxycholesterol in Koreans, Swedes and Tanzanians were 29.3, 26.8 and 21.9 ng ml À1 , respectively.
8 CYP3A5 genetic polymorphisms appear not to have a major function for the observed differences in CYP3A activity, because when comparing non-CYP3A5 expressors only (CYP3A5*0/*0), Ethiopians display higher mean 4b-hydroxycholesterol concentration as well as 4b-hydroxycholesterol/cholesterol ratio than Swedes, Koreans or Tanzanians. It is presumed that genetic variations in CYP3A4 are unlikely to contribute for the variations in CYP3A activity. 4 Recently, we reported that the extent of DNA methylation is a new mechanism contributing to the large inter-individual differences in CYP1A2 gene expression. 28 The genetic, epigenetic or environmental basis for the observed ethnic variations in CYP3A activity remain to be investigated.
Correlation between the two CYP3A metrics 4b-hydroxycholesterol and omeprazole/omeprazole sulfone ratio was investigated in all subjects, in CYP3A5 expressors and in non-expressors separately (Figure 1) . In all subjects, there was a weak but significant correlation of omeprazole/ omeprazole sulfone ratio with 4b-hydroxycholesterol (r 2 ¼ 0.06) and 4b-hydroxycholesterol/cholesterol ratio (r 2 ¼ 0.07). The correlation was slightly stronger among CYP3A5 non-expressors, with the respective r 2 values being 0.10 and 0.23 reflecting mainly CYP3A4 activity. The overall weak correlation indicates that 4b-hydroxycholesterol and omeprazole sulfone do not measure exactly the same feature. Furthermore, CYP3A5 genotype was significantly associated with 4b-hydroxycholesterol and 4b-hydroxycholesterol/cholesterol ratio but not with omeprazole/omeprazole sulfone ratio indicating no significant role of CYP3A5 in omeprazole sulfoxidation. A recent study also reported a lack of association between CYP3A5 genotype and omeprazole/omeprazole sulfone ratio. 29 We reported previously a poor dose-response relationship in the formation of omeprazole sulfone whereas the 4b-hydroxycholesterol concentration steadily increased with increasing doses of rifampicine, a strong inducer of CYP3A, in healthy volunteers. 30 These observations reinforce the notion that 4b-hydroxycholesterol concentration and the 4b-hydroxycholesterol/cholesterol ratio are better markers than omeprazole/omeprazole sulfone ratio to determine total CYP3A activity.
We found no significant difference in omeprazole/omeprazole sulfone ratio between men and women. In contrast, plasma 4b-hydroxycholesterol concentrations were higher in women than in men. We further investigated whether this difference could be due to differences in cholesterol concentrations between men and women. Indeed, the mean plasma cholesterol level was significantly higher in women than in men. This was corrected for by using the 4b-hydroxycholesterol/cholesterol ratio for comparisons. The result indicated a significantly higher 4b-hydroxycholesterol/cholesterol ratio and hence CYP3A activity in women than in men.
Plasma 4b-hydroxycholesterol has been suggested as an endogenous CYP3A biomarker. It shows good correlation with another CYP3A marker, quinine/3-hydroxyquinine ratio. 8 Its plasma concentration increases in subjects treated with known CYP3A4 inducers such as carbamazepine, phenytoin, phenobarbital, rifampicin, ursodeoxycholic acid and efavirenz. 8, [30] [31] [32] [33] [34] [35] It was also shown that inhibitors of CYP3A4, ritonavir and itraconazol, reduce the plasma level of 4b-hydroxycholesterol. 35, 36 However, recently, TomalikScharte et al. 37 reported a weak correlation between cholesterol-and midazolam-based CYP3A metrics and hence questioned the validity of 4b-hydroxycholesterol as a CYP3A biomarker. As pointed out by Tomalik-Scharte et al. 37 cholesterol and midazolam metrics do not measure exactly the same thing. The same group previously reported that there was no relevant impact of the CYP3A5 alleles *3, *6 and *7 on midazolam metabolism. 38 This study in Ethiopians and a previous study in three other populations report a significant role of CYP3A5 genotype on plasma 4b-hydroxycholesterol formation. 8 Furthermore, the half-lives of 4b-hydroxycholesterol and midazolam are very different, 17 days 32 versus 1.8 h, respectively. 39 Thus, midazolam metrics is like a snap shot whereas 4b-hydroxycholesterol is an averaged measure over a long period of time. These differences may explain the diverging results reported by Tomalik-Scharte et al. A lack of correlation between the erythromycin breath test and midazolam clearance has been reported earlier. 40 The large inter-individual variations in the metabolic ratios within each genotype group, the extensive overlap of ratios between the different genotype groups plus the small Influence of sex and CYP3A5 genotype on total CYP3A activity number of individuals homozygous for the functional CYP3A5*1 allele suggest a minor role of the CYP3A5 genotype for personalized therapy. However, a recent study reported a significant association of CYP3A5 genotype with acute rejection episodes in renal allograft recipients treated with tacrolimus and suggested initial dose adjustment according to the CYP3A5 genotype. 41 Although CYP3A5 may not appear as important as CYP3A4 in drug metabolism, its expression and genotype may have clinical importance in black populations, where the enzyme is expressed to a larger extent.
In conclusion, our results indicate that both CYP3A5 genotype and sex are important determinants for total CYP3A activity in Ethiopians; 4b-hydroxycholesterol is a useful endogenous biomarker for total CYP3A activity whereas omeprazole slufoxidation probably reflects mainly CYP3A4 activity. The finding of a unique distribution of CYP3A5 genetic variants and most importantly the high total CYP3A activity in Ethiopians warrants further investigations to evaluate their clinical relevance.
